Heart failure & cardiomyopathies
Dapagliflozin in Patients with Heart Failure and Previous Myocardial Infarction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
Authors' conclusion
History of MI confers increased risks of adverse cardiovascular outcomes in patients with HF across the LVEF spectrum, even among those with preserved ejection fraction. Dapagliflozin consistently and safely reduces the risk of cardiovascular death or worsening HF, regardless of previous MI.
Study context
- Population
- Symptomatic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤40% (DAPA-HF) or >40% (DELIVER), with or without previous myocardial infarction (MI)3,731 (34%) with previous MI
- Participants
- 11,007 participants
- Comparison
- Dapagliflozin vs placebo, by previous MI
- Outcome
- CV death or worsening HF
Methodological detailssubgroup analysis by history of MI
- Subgroup analysis by history of MI
Pooled result
As reported in the abstract
CV death or worsening HF, by previous MI
Dapagliflozin vs PlaceboHazard ratio (95% CI)
Previous MI
0.83(0.72–0.96)
No previous MI
0.76(0.68–0.85)
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| CV death or worsening HF: previous MIvs no previous MI (covariate-adjusted) | 1.12 (1.02–1.24) | |
| 0.512Hazard ratio (log scale) |
Key secondary outcomes
- Consistent benefits of dapagliflozin irrespective of previous MI
Original publication
Dapagliflozin in Patients with Heart Failure and Previous Myocardial Infarction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. Eur J Heart Fail. Published 15 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →